Intravenous Ketamine for Treatment-Resistant Depression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Intravenous Ketamine for Treatment-Resistant Depression — Stella

Home/Depressive Disorder, Treatment-Resistant/

View on ClinicalTrials.gov

Recruiting

Back to Depressive Disorder, Treatment-Resistant trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Mayo Clinic in Rochester, Rochester, Minnesota

Key details

Phase

Safety & dosing

Sponsor

Mayo Clinic

Collaborators

National Center for Advancing Translational Sciences (NCATS)

Enrollment target

~30 participants

Started

February 2025

Primary completion

December 2027

Age range

18 Years – 65 Years

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.